MAPT and Alzheimer disease: The comprehensive TMTc workflow, validated via immunoblotting, provides high-resolution, quantitative profiling of sarkosyl-insoluble, tau-enriched protein fractions from AD brain tissue, revealing both known and novel proteins associated with disease-relevant aggregates.